伊米奎莫德
医学
光化性角化病
皮肤病科
氟尿嘧啶
光化性角化病
胸苷酸合酶
基底细胞
内科学
化疗
作者
R. Maxwell Regester,Amy C. Cannella,Julianna Hirz,Brian Sayles,Stacie Schlange,Atk Rau,Harlan Sayles,Anthony J. Griess
标识
DOI:10.1016/j.jaad.2024.01.065
摘要
To the Editor: Actinic keratoses (AK) represent the second most common dermatologic diagnosis in the US.1,2 The direct costs of AK therapy in the US health care system approximate $920 million annually.3 An estimated 65% of cutaneous squamous cell carcinoma lesions originate from pre-existing AKs.2,4 Widely used topical therapies for AKs include imiquimod, an immune response modifier, and 5-fluorouracil (5-FU), a thymidylate synthase inhibitor. Reported regimens and clearance rates are highly variable for both drugs, ranging from 52% to 94% for 5-FU and 66% to 87% for imiquimod.
科研通智能强力驱动
Strongly Powered by AbleSci AI